A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.
Video content above is prompted by the following question:
a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?
b. How would the introduction of an oral therapy for CSU influence your treatment decisions?
Pediatric Food Allergy Diagnosis Could Be Streamlined By New Scoring System
May 10th 2025A newly developed Naples Pediatric Food Allergy grading scale, incorporating clinical history and examination, shows promise in streamlining the diagnosis of food allergies in children, potentially reducing delays and health care burdens.
Read More
Dermatology Impacts Climate Change With High Carbon Emissions, Path to Sustainability
May 7th 2025There are significant environmental impacts of dermatological practices that call for interdisciplinary collaboration and policy changes to promote sustainability and reduce carbon emissions within the field.
Read More
Study Highlights Unmet Needs in Measuring Patient Experiences in Alopecia Areata
April 29th 2025Significant unmet needs were found among high-quality validation studies on the internal structure of patient-reported outcome measures (PROMs) specific to alopecia areata (AA), a common hair loss condition with substantial quality of life impacts.
Read More